Revenue (Tables)

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

	Three Months Ended March 31,
	2020							2019
	United States (U.S.) (1)			Outside U.S.		Total		U.S. (1)		Outside U.S.		Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®	$	929.5		$	299.9	$	1,229.4	$	665.6	$	214.1	$	879.7
Humalog® (2)	398.6			297.2		695.8		448.6		282.2		730.8
Humulin®	214.1			101.5		315.7		201.3		96.4		297.7
Basaglar®	230.4			73.3		303.7		198.2		53.2		251.4
Jardiance (3)	144.6			122.9		267.5		125.2		78.4		203.6
Trajenta (4)	28.7			64.5		93.2		47.4		84.6		131.9
Other Diabetes	45.3			18.4		63.6		33.1		24.7		57.9
Total Diabetes	1,991.2			977.7		2,968.9		1,719.4		833.6		2,553.0
Oncology:
Alimta®	324.2			235.8		560.1		281.8		217.4		499.2
Cyramza®	89.1			149.9		239.0		75.1		123.2		198.3
Verzenio®	129.4			58.6		188.0		93.5		15.9		109.4
Erbitux®	117.8			13.0		130.8		113.3		5.1		118.4
Other Oncology	(2.6		)	86.3		83.6		30.2		57.3		87.4
Total Oncology	657.9			543.6		1,201.5		593.9		418.9		1,012.7
Immunology:
Taltz®	327.5			116.0		443.5		180.8		71.7		252.5
Olumiant®	11.3			128.4		139.7		6.4		75.7		82.1
Other Immunology	2.6			—		2.6		—		—		—
Total Immunology	341.4			244.4		585.8		187.2		147.4		334.7
Neuroscience:
Cymbalta®	11.6			198.8		210.4		10.3		153.8		164.1
Zyprexa®	11.2			87.2		98.4		9.3		97.9		107.2
Emgality®	67.3			6.7		74.0		12.2		2.1		14.2
Other Neuroscience	20.2			60.5		80.7		19.3		88.2		107.6
Total Neuroscience	110.3			353.2		463.5		51.1		342.0		393.1
Other:
Forteo®	122.5			149.8		272.4		125.9		187.0		312.9
Cialis®	26.1			167.0		193.0		143.2		164.9		308.2
Other	79.4			95.3		174.7		70.1		107.6		177.6
Total Other	228.0			412.1		640.1		339.2		459.5		798.7
Revenue	$	3,328.8		$	2,531.0	$	5,859.8	$	2,890.8	$	2,201.4	$	5,092.2

Numbers may not add due to rounding.

⁽¹⁾ U.S. revenue includes revenue in Puerto Rico.

⁽²⁾ Humalog revenue includes Insulin Lispro.

⁽³⁾ Jardiance revenue includes Glyxambi^®, Synjardy^®, and Trijardy^® XR.

⁽⁴⁾ Trajenta revenue includes Jentadueto^®_. 

.

The following table summarizes revenue by geographical area:

	Three Months Ended March 31,
	2020		2019
Revenue—to unaffiliated customers (1):
U.S. (2)	$	3,328.8	$	2,890.8
Europe	1,061.0		900.3
Japan	592.3		543.7
China	267.3		211.2
Other foreign countries	610.4		546.2
Revenue	$	5,859.8	$	5,092.2

Numbers may not add due to rounding.

⁽¹⁾ Revenue is attributed to the countries based on the location of the customer.

⁽²⁾ U.S. revenue includes revenue in Puerto Rico.

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:

	Three Months Ended March 31,
	2020		2019
Net product revenue	$	5,403.5	$	4,692.3
Collaboration and other revenue (1)	456.3		399.9
Revenue	$	5,859.8	$	5,092.2

⁽¹⁾ Collaboration and other revenue associated with prior period transfers of intellectual property was $35.4 million and $35.5 million during the three months ended March 31, 2020 and 2019, respectivel

Schedule of amounts recorded for contract liabilities

The following table summarizes contract liability balances:

	March 31, 2020		December 31, 2019
Contract liabilities	$	307.8	$	264.6